SYGNIS AG announces management changes

Co-CEO Pilar de la Huerta to resign from the management board and to transition to the supervisory board.

SYGNIS AG announced on June 5, 2017 changes to the management team. Pilar de la Huerta resigned from her position as member of the management board with effect of the upcoming annual shareholders meeting on July 7, 2017 in order to take on the role of Chief Executive Officer (CEO) in the pharmaceutical industry. With her resignation, Dr. Heikki Lanckriet (previously Co-CEO) will become CEO of SYGNIS AG and will also retain his role as Chief Scientific Officer. Pilar de la Huerta will join the Supervisory Board of SYGNIS AG, subject to the confirmation of the AGM. 

SYGNIS AG specializes in the development and commercialization of proprietary technologies and offers a wide range of commercial products addressing key challenges in molecular biology. With the 2016 acquisition of Expedeon Holdings, Ltd. based in the UK, SYGNIS added a complementary proteomics product portfolio. Resulting from this significant expansion, SYGNIS’ product portfolio now covers the entire workflow of molecular biology. In addition, SYGNIS acquired the profitable U.S.-based life sciences tools company C.B.S. Scientific in December 2016 to further expand its product offering. The products of SYGNIS Group are sold through a direct sales force and several distribution partners in Europe, the U.S. and Asia. SYGNIS AG has offices in Germany, Spain and the UK, production sites in the UK and the U.S. as well as sales offices in Asia.

Further information:

09.06.2017 - 09:38